Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans
Trial status: Open for Enrollment
Why is this study being done?
Aim I: Hypothesis: The extent of endothelial dysfunction will correlate with production of Lp-PLA2 and oxidative stress and correlates with the tissue characteristics of plaque vulnerability. The investigators will define the systemic and coronary gradient and production of markers of inflammation and oxidative stress and the presence of coronary endothelial dysfunction in patients with early coronary atherosclerosis.
Aim II: Hypothesis: The distribution of Lp-PLA2 on the LDL is associated with greater coronary endothelial dysfunction and correlates with the degree coronary atherosclerosis and plaque vulnerability. The investigators will define the distribution of Lp-PLA2 in patients with early coronary atherosclerosis and endothelial dysfunction.
Who is eligible to participate?
- Patients undergoing coronary angiography including endothelial function testing
- male and female
- age 18 up to age 85
- Heart failure with ejection fraction less that 40%
- unstable angina
- myocardial infarction or angioplasty within 6 months prior to entry into the study
- use of investigational agents within 1 month of entry into the study
- patients who require treatment with positive inotropic agents other than digoxin during the study
- patients with cerebrovascular accident within 6 months prior to entry into the study
- significant endocrine, hepatic or renal disorders
- local or systemic infectious disease within 4 weeks prior to entry into study
- pregnancy or lactation (women of child-bearing age will have a pregnancy test prior to angiogram)
- mental instability
- federal medical center inmates
- hemoglobin less than 12 mg/dL
- severe asthma